Kailera Therapeutics, Inc. KLRA
NASDAQ
Recommendation
Dividend Power Score
Day's Range
$12.73$13.44
Latest Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 82.51% | 33.49% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 295.98% | 313.82% | |||
| Operating Income | -295.98% | -313.82% | |||
| Income Before Tax | -284.52% | -338.55% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -284.52% | -338.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -284.52% | -338.55% | |||
| EBIT | -295.98% | -313.82% | |||
| EBITDA | -296.46% | -314.61% | |||
| EPS Basic | -- | -- | |||
| Normalized Basic EPS | -- | -- | |||
| EPS Diluted | -- | -- | |||
| Normalized Diluted EPS | -- | -- | |||
| Average Basic Shares Outstanding | -- | -- | |||
| Average Diluted Shares Outstanding | -- | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||